首页 > 市场调查报告书 > 製药

消化器

市场调查报告书

商品编码

1544659

发炎性肠道疾病治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Inflammatory Bowel Disease Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月11日 | 出版商:

Global Market Insights Inc. | 英文 100 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于 IBD 的流行和人们对该疾病的认识不断提高，预计 2024 年至 2032 年全球发炎性肠道疾病治疗市场的复合年增长率将达到 6.1%。根据美国国立卫生研究院 (NIH) 的报告，2023 年全球生物技术研发支出将达到 4,000 亿美元。这种投资热潮支持了 IBD 创新疗法的开发，例如生物製剂和标靶治疗。不断扩大的患者群体和对个人化治疗选择的需求正在创造积极的行业前景。

生物技术和製药的进步带来了创新疗法，可积极改善患者的治疗效果。此外，製药公司对研发的投资不断增加，以及研究机构和生技公司之间合作的激增，正在加速发炎性肠道疾病治疗市场的成长。

发炎性肠道疾病治疗产业根据治疗类型、药物类别、给药途径、配销通路和地区进行分类。

到 2032 年，由于诊断病例数量的增加和人们对该疾病的认识不断提高，溃疡性结肠炎细分市场将经历可观的增长。溃疡性结肠炎是一种影响结肠的慢性炎症，通常需要专门的治疗策略，从而导致对标靶治疗和治疗进展的需求增加。随着医疗保健提供者和患者寻求更有效和量身定制的治疗方案来控制症状和改善生活质量，对溃疡性结肠炎的关注不断加强，从而扩大了细分市场的成长。增强的诊断技术和患者教育促进了需求的增加。

到 2032 年，由于患者可及性和便利性的提高，电子商务领域将占据重要的发炎性肠道疾病治疗市场。线上平台有助于直接购买药物和治疗相关产品，从而更容易获得各种专业和利基治疗。这种增加的可用性对于偏远或服务不足地区的患者是有益的，因为这些地区获得实体药房的机会可能有限。电子商务管道提供简化的购买流程，并提供详细的资讯和患者评论，帮助消费者做出明智的决定。

在研究期间，欧洲发炎性肠道疾病治疗市场将录得令人印象深刻的成长率，这得益于不断增加的医疗保健支出，提高了先进治疗的可负担性。该地区强有力的监管框架支持新疗法的开发和批准，促进治疗领域的创新。 IBD 在欧洲的盛行率不断上升，加上公众意识的提高和早期诊断，导致对有效管理解决方案的需求更高。完善的研究机构和製药公司网络正在加速新疗法的开发，帮助市场成长。

产业生态系统分析
产业影响力
- 成长动力
  - IBD 盛行率增加
  - 技术进步
  - 优惠报销政策
  - 对 IBD 症状的认识不断提高并进行早期诊断
- 产业陷阱与挑战
  - 严格的监管场景
  - 治疗费用高
成长潜力分析
报销场景
监管环境
流行病学情景
未来市场趋势
管道分析
2023 年定价分析
品牌分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

主要趋势
克罗恩病
溃疡性结肠炎

第 6 章：市场估计与预测：按药物类别，2021 - 2032 年

主要趋势
肿瘤坏死因子抑制剂
氨基水杨酸盐
皮质类固醇
白血球介素抑制剂
JAK抑制剂
抗整合素
其他药物类别

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

主要趋势
可注射
口服

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
零售药房
网路药房

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

AbbVie Inc
Amgen Inc.
Biogen
CELLTRION INC
Dr Falk Pharma UK Ltd
Ferring B.V.
Ferring B.V.
Johnson and Johnson
Lilly
Novartis AG
Pfizer Inc
Takeda Pharmaceutical Company Limited
Tillotts Pharma AG
UCB Group

简介目录

Product Code: 10194

Global Inflammatory Bowel Disease Treatment Market is projected to achieve a 6.1% CAGR from 2024 to 2032, catapulted by the prevalence of IBD and growing awareness of this condition. As per the U.S. National Institutes of Health (NIH) report, global spending on biotechnology R and D reached USD 400 billion in 2023. This upsurge in investment supports the development of innovative therapies for IBD, such as biologics and targeted treatments. The expanding patient population and the need for personalized treatment options are creating a positive industry outlook.

Advances in biotechnology and pharmaceuticals have resulted in innovative therapies that are positively improving patient outcomes. Additionally, growing investment in research and development by pharmaceutical companies and a surge in collaborations between research institutions and biotech firms are accelerating inflammatory bowel disease treatment market growth.

The inflammatory bowel disease treatment industry is sorted based on treatment type, drug class, route of administration, distribution channel, and region.

The ulcerative colitis segment will experience a decent growth rate through 2032, due to an increase in the number of diagnosed cases and growing awareness of the condition. Ulcerative colitis, a chronic inflammatory condition affecting the colon, often requires specialized management strategies, leading to heightened demand for targeted treatments and therapeutic advancements. As healthcare providers and patients seek more effective and tailored treatment options to manage symptoms and improve quality of life, the focus on ulcerative colitis has intensified, amplifying segment growth. Enhanced diagnostic techniques and patient education are contributing to the increased demand.

By 2032, the e-commerce segment will hold a significant inflammatory bowel disease treatment market share, owing to improved patient accessibility and convenience. Online platforms facilitate the direct purchase of medications and treatment-related products, allowing for easier access to a wide range of specialty and niche treatments. This increased availability is beneficial for patients in remote or underserved areas, where access to physical pharmacies may be limited. E-commerce channels offer a streamlined purchasing process and provide detailed information and patient reviews, helping consumers make informed decisions.

Europe inflammatory bowel disease treatment market will record an impressive growth rate over the study period, bolstered by the increasing healthcare expenditure enhancing the affordability of advanced treatments. The strong regulatory framework in the region supports the development and approval of new therapies, fostering innovation in the treatment landscape. The rising prevalence of IBD in Europe, coupled with greater public awareness and early diagnosis, is leading to a higher demand for effective management solutions. A well-established network of research institutions and pharmaceutical companies is accelerating the development of novel treatments, aiding market growth.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of IBD
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Favorable reimbursement policies
  - 3.2.1.4 Growing awareness and early diagnosis of IBD symptoms
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulatory scenario
  - 3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Epidemiological scenario
3.7 Future market trends
3.8 Pipeline analysis
3.9 Pricing analysis, 2023
3.10 Brand analysis
3.11 Porter's analysis
3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Crohn's disease
5.3 Ulcerative colitis

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 TNF inhibitors
6.3 Aminosalicylates
6.4 Corticosteroids
6.5 IL inhibitors
6.6 JAK inhibitors
6.7 Anti-integrin
6.8 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Injectable
7.3 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa